About
We want to do more than just treat monogenic CNS disease. We want to eradicate it.
We want to do more than just treat monogenic CNS disease. We want to eradicate it.
This is why we are singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), both in rare and large patient populations.
We were founded in partnership with The University of Texas Southwestern Medical Center (UT Southwestern) to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we have created a powerful engine to develop transformative therapies with the potential to dramatically improve patients’ lives.
Do what we love and love what we do
Think big, be courageous
For each other, for patients
Respect each other, explore differences, unite as a team
We are rooted in the heart of Dallas, not far from the iconic Spindletop oil field.
Through the generations, these hardworking explorers ultimately went on to fund the very research being conducted at UT Southwestern today.
At Taysha, we embrace the same diligent, trailblazing mindset our Texan ancestors were known for.
As the largest oil production center at the turn of the century, Spindletop fueled Texas’ economy and a new breed of ‘wildcatters’ – the individuals who drilled new, exploratory oil wells.
Our partnership with UT Southwestern is different from traditional collaborations between industry and academia.
Through our partnership, we are able to leverage the collective expertise of UT Southwestern researchers, clinicians and investigators with decades of experience in conducting cutting-edge research and providing clinical care. This includes the esteemed scientists who lead the UT Southwestern Gene Therapy Program: Steven Gray, Ph.D., and Berge Minassian, M.D.
We have access to UT Southwestern’s faculty, GMP viral vector manufacturing facility and integrated research and clinical care approach. Together, we believe this will enable us to advance our development programs with speed and scale.
We’ve assembled the experts.
Our team is comprised of some of the most accomplished and knowledgeable gene therapy scientists and CNS disease experts. Together – armed with our unrelenting, patient-first focus – we are helping bring new cures to life.
Tracy M. Porter, M.Ed., SPHR
/in Leadership TeamChief People Officer
Sukumar Nagendran, M.D.
/in Board of Directors, Leadership TeamPresident and Head of Research and Development
Sean Nolan
/in Board of Directors, Leadership TeamChief Executive Officer and Board Chairman
Sean McAuliffe
/in Leadership TeamChief Business Officer
Emily McGinnis
/in Leadership TeamChief Patient Advocacy and External Affairs Officer
Fred Porter, Ph.D.
/in Leadership TeamChief of Staff and Technical Operations Officer
Kamran Alam, CPA, MBA
/in Leadership TeamChief Financial Officer